

Ref: FOI/CAD/ID 2956

Please reply to:
FOI Administrator
Trust Management
Maidstone Hospital
Hermitage Lane
Maidstone
Kent
ME16 9QQ
Email: mtw-tr.foiadmin@nhs.net

24 September 2015

Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to Multiple Sclerosis.

I have a Freedom of Information request regarding Multiple Sclerosis – in your organisation, how many patients with Multiple Sclerosis have been treated with MS disease modifying drugs in the past 12 months?

1. Please provide the number of patients by treatment for the following drugs:

Aubagio (teriflunomide)
Avonex (interferon beta-1a)
Betaferon (interferon beta-1b)
Copaxone (glatiramer acetate)
Extavia (beta interferon-1b)
Gilenya (fingolimod)
Lemtrada (alemtuzumab)
Rebif (beta interferon-1a)
Tecfidera (dimethyl fumarate)
Tysabri (natalizumab)
Ampyra (Fampyra)
Peginterferon beta-1a
Others

Aubagio (teriflunomide)	1
Avonex (interferon beta-1a)	33
Betaferon (interferon beta-1b)	16
Copaxone (glatiramer acetate)	43
Extavia (beta interferon-1b)	
Gilenya (fingolimod)	3 *
Lemtrada (alemtuzumab)	

Rebif (beta interferon-1a)	36
Tecfidera (dimethyl fumarate)	32
Tysabri (natalizumab)	**
Ampyra (Fampyra)	
Peginterferon beta-1a	
Others	

* Patients are seen at Kings College Hospital for one year before their care is transferred to Maidstone and Tunbridge Wells NHS Trust.

** Tysabri patients are seen at Kings College Hospital.